These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 12902992)
1. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Greenwald MK; Johanson CE; Moody DE; Woods JH; Kilbourn MR; Koeppe RA; Schuster CR; Zubieta JK Neuropsychopharmacology; 2003 Nov; 28(11):2000-9. PubMed ID: 12902992 [TBL] [Abstract][Full Text] [Related]
2. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Greenwald M; Johanson CE; Bueller J; Chang Y; Moody DE; Kilbourn M; Koeppe R; Zubieta JK Biol Psychiatry; 2007 Jan; 61(1):101-10. PubMed ID: 16950210 [TBL] [Abstract][Full Text] [Related]
3. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Zubieta J; Greenwald MK; Lombardi U; Woods JH; Kilbourn MR; Jewett DM; Koeppe RA; Schuster CR; Johanson CE Neuropsychopharmacology; 2000 Sep; 23(3):326-34. PubMed ID: 10942856 [TBL] [Abstract][Full Text] [Related]
4. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Greenwald MK; Comer SD; Fiellin DA Drug Alcohol Depend; 2014 Nov; 144():1-11. PubMed ID: 25179217 [TBL] [Abstract][Full Text] [Related]
5. Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers. Woodcock EA; Lundahl LH; Greenwald MK Drug Alcohol Depend; 2015 Jan; 146():89-96. PubMed ID: 25479914 [TBL] [Abstract][Full Text] [Related]
6. Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance. Greenwald MK; Johanson CE; Schuster CR Drug Alcohol Depend; 1999 Oct; 56(3):191-203. PubMed ID: 10529021 [TBL] [Abstract][Full Text] [Related]
7. Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence. Kakko J; von Wachenfeldt J; Svanborg KD; Lidström J; Barr CS; Heilig M Biol Psychiatry; 2008 Jan; 63(2):172-7. PubMed ID: 17850768 [TBL] [Abstract][Full Text] [Related]
8. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Greenwald MK; Schuh KJ; Hopper JA; Schuster CR; Johanson CE Psychopharmacology (Berl); 2002 Apr; 160(4):344-52. PubMed ID: 11919661 [TBL] [Abstract][Full Text] [Related]
9. A randomized trial of one-day vs. three-day buprenorphine inpatient detoxification protocols for heroin dependence. Hopper JA; Wu J; Martus W; Pierre JD J Opioid Manag; 2005; 1(1):31-5. PubMed ID: 17315409 [TBL] [Abstract][Full Text] [Related]
10. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. Comer SD; Collins ED J Pharmacol Exp Ther; 2002 Nov; 303(2):695-703. PubMed ID: 12388653 [TBL] [Abstract][Full Text] [Related]
11. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Kuhlman JJ; Levine B; Johnson RE; Fudala PJ; Cone EJ Addiction; 1998 Apr; 93(4):549-59. PubMed ID: 9684393 [TBL] [Abstract][Full Text] [Related]
12. Buprenorphine and nor-buprenorphine levels in head hair samples from former heroin users under Suboxone® treatment. Belivanis S; Tzatzarakis MN; Vakonaki E; Kovatsi L; Mantsi M; Alegakis A; Kavvalakis MP; Vynias D; Tsatsakis AM Drug Test Anal; 2014 Jun; 6 Suppl 1():93-100. PubMed ID: 24817054 [TBL] [Abstract][Full Text] [Related]
13. Rapid detoxification of heroin dependence by buprenorphine. Liu ZM; Cai ZJ; Wang XP; Ge Y; Li CM Zhongguo Yao Li Xue Bao; 1997 Mar; 18(2):112-4. PubMed ID: 10072959 [TBL] [Abstract][Full Text] [Related]
14. Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin-evoked dopamine release in rats. Isaacs DP; Leman RP; Everett TJ; Lopez-Beltran H; Hamilton LR; Oleson EB Neuropsychopharmacol Rep; 2020 Dec; 40(4):355-364. PubMed ID: 32935483 [TBL] [Abstract][Full Text] [Related]
15. Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women. Concheiro M; Jones HE; Johnson RE; Choo R; Huestis MA Ther Drug Monit; 2011 Oct; 33(5):619-26. PubMed ID: 21860340 [TBL] [Abstract][Full Text] [Related]
16. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. White J; Bell J; Saunders JB; Williamson P; Makowska M; Farquharson A; Beebe KL Drug Alcohol Depend; 2009 Jul; 103(1-2):37-43. PubMed ID: 19403243 [TBL] [Abstract][Full Text] [Related]
17. Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data. Hjelmström P; Banke Nordbeck E; Tiberg F Drug Dev Ind Pharm; 2020 Jan; 46(1):1-7. PubMed ID: 31914818 [No Abstract] [Full Text] [Related]
18. Differential regional effects of methadone maintenance compared to heroin dependence on mu-opioid receptor desensitization in rat brain. Martin TJ; Kahn WR; Xiao R; Childers SR Synapse; 2007 Mar; 61(3):176-84. PubMed ID: 17152089 [TBL] [Abstract][Full Text] [Related]
19. Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. Kling MA; Carson RE; Borg L; Zametkin A; Matochik JA; Schluger J; Herscovitch P; Rice KC; Ho A; Eckelman WC; Kreek MJ J Pharmacol Exp Ther; 2000 Dec; 295(3):1070-6. PubMed ID: 11082442 [TBL] [Abstract][Full Text] [Related]